~~<i id='11047239BA'><strike id='11047239BA'><tt id='11047239BA'><pre id='11047239BA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：explore 2025-09-29 22:53:34 - browse：2981

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA approves Leqembi, a milestone in Alzheimer’s treatment

knowledge

entertainment

focus

knowledge

hotspot

1:10Asthetemperatureclimbs,sodoesthedangerforchildrenleftinhotvehicles.STOCKPHOTO/GettyImagesAFlorid

WSS

How corporate America is slashing DEI workers amid backlash to diversity programs

Listen: BridgeBio's big week & Lilly's Alzheimer's data

With fresh data, a dynamic duo powers Eli Lilly to new heights

New chart reveals military’s vast involvement in Operation Warp Speed

Reframing the conversation around gain

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

hotspot

leisure time

knowledge

New air purifier tech could be key to improving indoor air quality

It's time to take a new tack for treating Alzheimer's

Guidelines to prevent youth baseball injuries need more muscle

What is artificial intelligence? Experts weigh in

The cancer drug shortage isn’t new — and neither are the solutions

How corporate America is slashing DEI workers amid backlash to diversity programs

In age of alternative facts, a scholarly course on calling out crap

With fresh data, a dynamic duo powers Eli Lilly to new heights

In age of alternative facts, a scholarly course on calling out crap

A former Republican legislative candidate has been charged for his role in the US Capitol riot

entertainment

Neutralizing antibodies against HIV shows promise in children

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Neutralizing antibodies against HIV shows promise in children

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

entertainment

focus

knowledge

hotspot